Research programme: serotonin 2 receptor antagonists - AnaMar

Drug Profile

Research programme: serotonin 2 receptor antagonists - AnaMar

Alternative Names: AM260; AM260 TASS; Am260, TASS; AMAP 312; AMAP332

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnaMar Medical
  • Developer AcurePharma; AnaMar AB
  • Class Small molecules
  • Mechanism of Action Serotonin 2 receptor antagonists; Serotonin 2B receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Inflammatory pain
  • Research Idiopathic pulmonary fibrosis
  • No development reported Osteoarthritis; Rheumatoid arthritis

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammatory-pain in Sweden (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Osteoarthritis in Sweden (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Rheumatoid-arthritis in Sweden (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top